National Cancer Institute (nci)

This study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…

This study tests whether adding the drug acalabrutinib to standard chemotherapy can help more people with untreated diffuse large B-cell lymphoma be cured. About 132 adults with this aggressive lymphoma will take acalabrutinib pills twice daily for up to 14 days, then receive sta…

This study tests a new type of focused radiation (SBRT) to cure early-stage prostate cancer that hasn't spread. Instead of treating the whole prostate, only the tumor is targeted, which may reduce side effects. About 42 men with low- or intermediate-risk prostate cancer will rece…

This early-stage trial tests a new vaccine called RG1-VLP in 18 healthy women to see if it is safe and can trigger an immune response against HPV types not covered by current vaccines. HPV is a common infection that can cause certain cancers. The goal is to find the best dose and…

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This phase II trial tests whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery helps patients with recurrent or persistent head and neck cancer. About 180 participants with PD-L1 positive tumors will receive either carboplatin and paclitaxel, or thos…

This phase 2 trial tests whether three antibody-drug conjugates (ADCs) can treat advanced solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). Participants will have their tumor's proteins measured, then receive a matched ADC. The goal is to see if…

This early-phase trial tests a drug called pidnarulex (CX-5461) in about 50 people with aggressive B-cell lymphomas that have not responded to standard treatments. The goal is to find the best dose and check if the drug is safe and can shrink tumors. Participants will also have b…

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, depending on the dose level. The main goal is to find a safe sche…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults with …

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—for people with multiple myeloma that has returned or is no longer responding to treatment. The goal is to find the safest and most effective dose. About 26 participants will receive the combi…

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better target and attack cancer c…

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab to standard chemotherapy (carboplatin and paclitaxel) before surgery can improve outcomes for people with sinonasal squamous cell carcinoma. About 108 participants with stage III or IV disease will be …

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy plus the immunotherapy drug atezolizumab. It compares continuing atezolizumab alone versus adding radiation therapy to the chest and any remaining tumors. The g…

This Phase 1 trial tests a new treatment for people with advanced solid tumors that express a protein called GPC3, including liver cancer. The treatment uses the patient's own T cells, which are modified in a lab to better recognize and attack cancer cells. Participants receive c…

This early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects.…

This early-phase trial is testing whether combining two drugs—abemaciclib and 5-fluorouracil—is safe and tolerable for people with metastatic colorectal cancer that has not responded to standard treatments. About 39 participants will receive the drug combination to find the best …

This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe dose and see if it helps control the tumor. About 32 adults with resectable recurrent adrenocortical carcinoma will receive daily radiatio…

This study tests a combination of two drugs, tovorafenib and rituximab, in people with hairy cell leukemia that has returned or not responded to treatment, and also compares it to standard therapy for newly diagnosed patients. Tovorafenib blocks a protein that helps cancer grow, …

This phase 2 trial tests whether adjusting the dose of the cancer drug belinostat based on a person's genetic makeup can improve treatment for high-grade neuroendocrine carcinomas. Researchers will give 60 participants different doses of belinostat along with standard chemotherap…

This phase II trial compares two treatments for high-grade T1 bladder cancer that hasn't spread. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy (cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C) plus radiation.…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the best dose and see if the drug can shrink or slow the cancer. Participants take the drug by mouth dail…

This early-phase trial tests a combination of two drugs—temozolomide and M1774—in people with advanced solid tumors that have spread. Temozolomide damages cancer cell DNA, while M1774 blocks enzymes that help cancer grow. The goal is to find the best dose and see if the combo can…

This early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a is a smart drug that delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks ca…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors and improve …

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This study tests two non-chemotherapy drugs, PDS01ADC and M7824, for people with advanced Kaposi sarcoma (KS) that has not responded well to prior treatment. The drugs work by helping the immune system recognize and attack tumors. About 80 adults aged 18 and older will receive th…

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adult…

This study is for people with high-risk stage III-IV head and neck cancer who have had surgery to remove the tumor. It compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and atezolizu…

This study tests a drug called selinexor combined with standard radiation for children and young adults with newly diagnosed, fast-growing brain tumors (DIPG or HGG). The goal is to find the safest dose and see if the combination can shrink tumors. About 132 participants will tak…

This study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive gynecologic or other solid tumors (excluding breast cancer). About 70 adults will be randomly assigned to one of the two treatments. The goal is to see if the …

This study tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can help people with HPV-related throat cancer avoid radiation and its side effects. About 70 adults with newly diagnosed, surgically removable throat cancer will receive either chemo alo…

This study tests a new drug (CDX-1140) combined with three other cancer drugs for people with advanced biliary tract cancer that has spread or come back after treatment. About 60 adults will receive the drugs through an IV and a pill over 21-day cycles for up to 2 years. The goal…

This study tests whether adding a targeted drug called gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or less fit adults with a specific genetic form of acute myeloid leukemia (FLT3 mutation) achieve a deeper remission. About 147 participan…

This early-stage trial tests a combination of two drugs—peposertib and a low-dose form of chemotherapy (liposomal doxorubicin)—in people with advanced soft tissue sarcomas that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This study looks at whether starting treatment early with two drugs (venetoclax and obinutuzumab) helps people with newly diagnosed, high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer and feel better compared to waiting until symptoms app…

This study tests a drug called erdafitinib in 30 adults with a specific type of brain tumor (glioma) that has come back or is getting worse. The tumor must have a certain gene change (FGFR-TACC fusion) and not have another common mutation (IDH-wild type). The drug works by blocki…

This early-phase study tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help treat advanced non-small cell lung cancer. About 23 adults whose cancer has returned or progressed after prior treatment will take the…

This study tests whether a combination of two drugs, enfortumab vedotin and pembrolizumab, can shrink or control rare cancers of the bladder, urinary tract, and testicles. About 68 adults with these rare tumors will receive the drugs through an IV, either every 3 weeks or every 4…

This study tests if a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced lung neuroendocrine tumors. The radioactive drug targets and kills tumor cells by binding to a protein on them. About 70 adults with these t…

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…

This early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the safest dose and se…

This early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically remov…

This early-stage trial tests a new gene therapy for people with certain T-cell lymphomas that have not responded to standard treatments. The therapy uses the patient's own white blood cells, modified in a lab to target a protein called CCR4 found on cancer cells. Up to 60 adults …

This phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…

This phase II trial is testing whether the combination of cabozantinib (a targeted drug) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head/neck cancers that have stopped responding to prior immunotherapy. Researchers will also see if two tumor bi…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This phase 2 trial tests an experimental therapy that takes white blood cells from a patient's tumor, grows them in large numbers in the lab, and gives them back along with the drug pembrolizumab (Keytruda). The goal is to see if this combination can shrink tumors in people with …

This phase 2 trial tests whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill leukemia cells, while…

This early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab together with radiation therapy after chemotherapy can help patients with muscle invasive bladder cancer avoid bladder removal surgery. About 111 participants who responded well to initial chemothe…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…

This study tests a combination of two drugs, palbociclib (a daily pill) and sasanlimab (a monthly shot), in people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if the combo can shrink tumors and to find the safest dose. About 100 ad…

This phase II trial tests whether two antibodies, glofitamab and obinutuzumab, can safely treat mantle cell lymphoma that has returned or not responded after CAR T-cell therapy. Twenty participants will receive the drugs and be monitored for tumor shrinkage and side effects. The …

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. About 60 adults with operable stage IB-IIIA NSCLC will receive …

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, including those with changes in the MYC or MYCN genes. The trial has two phases: first, finding the right dose, then checking if it works. Participants receive PLX038 intravenously every three weeks…

This early-stage trial is testing a drug called novobiocin, an antibiotic that blocks a protein cancer cells use to repair their DNA. It is for people with advanced solid tumors that have specific gene mutations (like BRCA) that already weaken DNA repair. The study aims to find t…

This phase 2 trial is testing whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy can improve outcomes for people with peritoneal mesothelioma, a rare cancer of the abdominal lining. About 66 participants will receive either standard treatment (carboplati…

This phase 2 trial tests whether the drug sacituzumab govitecan, alone or with atezolizumab, can shrink rare genitourinary tumors like certain bladder, kidney, and penile cancers. About 60 adults will receive the drugs intravenously in 21-day cycles for up to 5 years. The study a…

This study tests a lab-made protein called CYT107 in 55 adults with HIV and Kaposi sarcoma, a cancer linked to a weakened immune system. The protein is given as weekly shots for up to 4 weeks to try to increase T cells and shrink tumors. Researchers will monitor how well it works…

This phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests whether a stem cell transplant from a healthy donor can treat VEXAS syndrome, a rare and serious autoinflammatory disease. About 54 adults aged 18 to 75 with severe VEXAS that hasn't responded to standard treatments will receive donor stem cells after chemotherap…

This study is for people with recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants will …

This study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …

This early-phase trial tests the safety and best dose of an oral drug called ASTX727 (cedazuridine and decitabine) given with filgrastim (a white blood cell booster) to children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment, after the…

This study tests a new treatment for people with certain blood cancers, like leukemia and MDS. Doctors take a patient's own immune cells, modify them in a lab to recognize unique markers on their cancer cells, and then give them back. The goal is to see if this personalized thera…

This study tests a drug called mirdametinib in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. About 20 participants will take the drug to …

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see if this drug mix can make th…

This early-phase study tests a new drug, ASTX727, added to standard chemotherapy and immunotherapy for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink tumors or keep …

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This early-phase trial is testing a combination of two drugs, M1774 and ZEN-3694, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the combination can slow or stop cancer growth by blocking key enzymes. About 65 adults wit…

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…

This early-phase trial tests whether adding an experimental drug (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced bladder cancer whose tumors no longer respond to standard immunotherapy. The study will enroll 27 adults and focus on safety, side effects…

This study is for women with ovarian or endometrial cancer that has come back or not gone away and has a specific genetic change (RAS mutation). It compares a combination of two drugs (selumetinib and olaparib) against selumetinib alone. The goal is to see if the combination can …

This study is for younger adults with a certain type of acute myeloid leukemia (AML) that has an intermediate risk. It tests whether adding a targeted drug called venetoclax to standard chemotherapy can eliminate more cancer cells than standard treatment alone. About 153 particip…

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This study tests an experimental drug called zotiraciclib for people whose brain tumors (gliomas with IDH mutations) have returned after standard treatment. About 96 participants aged 15 and older will take the drug by mouth on a set schedule over 28-day cycles. The goal is to se…

This study tests a new two-drug treatment for people with advanced soft tissue sarcomas (cancers of the muscles, fat, or other connective tissues). The drugs, abemaciclib and gemcitabine, work together to stop cancer cells from growing. The trial will compare this new combo to th…

This study tests a new type of CAR T-cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not responded to standard treatments. Participants receive their o…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…

This study tests a new treatment for children and young adults with a specific type of leukemia (Ph+ or Ph-like B-ALL). The treatment combines standard chemotherapy with two targeted drugs: blinatumomab (which helps the immune system attack cancer) and dasatinib or imatinib (whic…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This study tests a combination of three drugs (bevacizumab, erlotinib, and atezolizumab) in people with advanced hereditary or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, blocking cancer growth signals, and helping the immune system a…

This study tests whether giving the immunotherapy drug durvalumab after surgery can prevent early-stage non-small cell lung cancer from coming back. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be watched closely (standard c…

This study tests the drug imatinib in adults with a faulty RUNX1 gene, which causes easy bleeding and a higher chance of blood cancers. The goal is to find the best dose that improves platelet function and reduces inflammation. Participants take imatinib daily for up to 84 days, …

This early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…

This early-phase trial tests a new drug, ZEN003694, combined with the standard chemotherapy capecitabine in 30 adults with advanced solid tumors that have spread or cannot be removed and no longer respond to standard treatments. The main goals are to find the safest dose and unde…

This phase 3 trial compares a two-drug combination (osimertinib plus bevacizumab) against osimertinib alone as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to see if adding bevacizumab helps control the cancer longer and improve…

This study tests a treatment called CAR T-cell therapy for people with advanced B-cell leukemias that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the body. The goal is to co…

This study tests whether a natural supplement called urolithin A, found in pomegranates, can reduce cell damage in prostate tumors. About 90 men with prostate cancer will take either the supplement or a placebo daily for 3 to 6 weeks before their prostate removal surgery. Researc…

This early-stage trial tests a combination of four drugs (methotrexate, rituximab, lenalidomide, and nivolumab) in people with primary CNS lymphoma, a rare type of brain cancer. The goal is to find the safest dose and see if adding lenalidomide and nivolumab can help control the …

This study compares three drug combinations for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 92 participants will receive either ibrutinib plus rituximab, zanubrutinib alone, or venetoclax plus rituximab. The goal is to see which approach lead…

This study tests a personalized vaccine plus three other drugs in 60 adults with advanced HER2-positive endometrial cancer that returned after treatment. The vaccine is made from each patient's own blood cells and targets the HER2 protein. The goal is to see if this combination c…

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to recognize and attack unique mutations in their tumor, then infuse the…

This study is for people living with HIV who also have a blood cancer that can be treated with a bone marrow transplant. Researchers want to see if a new mix of three drugs can safely prevent graft-versus-host disease, a common complication where donor cells attack the patient's …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery can help shrink high-risk liver cancer (intrahepatic cholangiocarcinoma). About 27 adults with resectable tumors will receive four cycles of the combination, then undergo sur…

This study tests whether adding the drugs M3814 and avelumab to standard radium-223 therapy can better control advanced prostate cancer that has spread to bones. About 90 adults with castration-resistant prostate cancer will receive either radium-223 alone or with one or both add…

This study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination shrinks tumors. About 36 adults with advanced or spreading NUT carcinoma w…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy can better prevent breast cancer from coming back in people with a high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 adults with stage II or III breast …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This early-phase study tests whether a new type of immunotherapy, called anti-CD22 CAR T cells, is safe for people with hairy cell leukemia (HCL) that has come back or not responded to standard treatments. Up to 27 adults will have their own immune cells collected, modified in a …

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if the combination shrinks tumors better than any single drug. About 314 adults with these rare cancers are being…

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers. The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to 8 years, with r…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This study tests whether adding the drug cabozantinib to standard chemotherapy works better than chemo alone for people under 40 with newly diagnosed osteosarcoma, a type of bone cancer. Cabozantinib blocks signals that help tumors grow and form blood vessels. The trial involves …

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests whether a newer drug, mosunetuzumab, works better than the standard drug rituximab for people with a rare type of Hodgkin lymphoma called NLPHL. About 70 participants will receive one of the two treatments. The goal is to see which drug helps patients live longer…

This early study tests a new pill called pidnarulex in 40 people with advanced solid tumors that have spread and stopped responding to standard treatments. The drug blocks a key enzyme cancer cells need to divide and repair their DNA, which may kill them. Researchers will check s…

This phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…

This study is for adults with advanced cancers like lung, liver, or melanoma who are eligible for the immunotherapy drug atezolizumab. Researchers want to see if giving a lower dose less often can still keep the drug at effective levels in the blood, potentially reducing side eff…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. …

This study tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can shrink tumors and stop HER2-positive endometrial cancer from coming back. About 360 people with stage I-IV endometrial cancer will receive either chemo alone or chemo plus the…

This study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…

This study tests a drug called tovorafenib in children and young adults (ages 6 months to under 22 years) whose Langerhans cell histiocytosis has returned or not responded to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The trial aims t…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests the drug abemaciclib in people aged 12 and older with NF1 who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if the drug can shrink or stabilize these nerve tumors. Participants take the drug twice daily for…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with a rare, aggressive type of neuroendocrine cancer that started outside the lungs. About 189 adults with advanced or metastatic disease will receive either chemo alone or …

This study tests whether combining two drugs, Lutathera and Olaparib, can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive Lutathera by IV every 8 weeks and take Olaparib pills twice daily. The goal is to fi…

This study tests a drug called PT-112 in people with thymoma or thymic carcinoma that has come back or not responded to standard treatment. The goal is to see if PT-112 can shrink tumors. About 53 adults will receive the drug by infusion every few weeks for up to 8 years, as long…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…

This study tests a daily pill called enasidenib for people with rare cancers of the nasal cavity or skull base that have a specific IDH2 gene mutation. The drug aims to slow or stop tumor growth in cancers that have spread or come back after other treatments. About 40 adults with…

This study tests whether adding enasidenib to standard treatment (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific gene mutation (IDH2). About 54 adults who have not had prior cancer therapy will be randomly assigne…

This study tests a new approach for people with aggressive blood cancers that have not responded well to standard treatments. It combines two powerful therapies: a half-matched bone marrow transplant and specially engineered CAR T-cells that target a protein called CD19 on cancer…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests an experimental drug called TPST-1495 in 38 people with familial adenomatous polyposis (FAP), an inherited condition that causes many polyps in the colon and small bowel and raises colon cancer risk. The drug works by blocking certain receptors linked to polyp gr…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests if a stem cell transplant from a healthy donor can help people aged 4 to 75 with severe immune system disorders. Participants receive chemotherapy and then donor stem cells, followed by a hospital stay and long-term monitoring. The goal is to see if the transplan…

This early-stage trial tests a new drug called metarrestin in people with solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumors may jo…

This early-phase trial tests whether adding an experimental drug (ZEN003694) to standard immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) is safe and tolerable for people with advanced triple-negative breast cancer that has spread. About 57 participants will receiv…

This early-stage trial tests whether combining two targeted therapies—sunitinib and a radioactive drug called Lutathera—is safe and effective for people with advanced pancreatic neuroendocrine tumors. About 24 participants will receive the combination to find the best dose and ch…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…

This study is for people with stage II to IIIB non-small cell lung cancer that has been surgically removed. It tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help keep the cancer from coming back and extend survival. About 1,210 participant…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without their cancer returning. About 478 children and young adults up to age 30 will be randomly assigned to receive either …

This early-phase trial tests a new drug (rhIL-15) combined with three standard cancer drugs for children and young adults (ages 3–35) whose neuroblastoma did not respond to treatment or returned. The main goal is to find a safe dose and check for side effects. Up to 40 participan…

This early-stage trial tests a drug called camonsertib combined with precise radiation for head and neck cancer that has returned or cannot be surgically removed. The study aims to find the safest dose and see if the combination can control tumor growth. About 39 adults with cert…

This study tests a drug called pacritinib in people with HIV who have two rare conditions caused by the Kaposi sarcoma herpesvirus (KSHV): KSHV-associated multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). These conditions cause severe, life-thre…

This study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS) — both those with and without HIV. The goal is to find a safe dose and see if it can shrink KS lesions or tumors. About 111 adults aged 18 and older with KS will take th…

This study tests a drug called M3814 combined with a special type of radiation for people with locally advanced pancreatic cancer (cancer that has spread nearby but not to distant organs). The goal is to find the safest dose and see if the combination helps stop tumor growth long…

This study tests whether the drug nivolumab can slow or stop the growth of certain cancers linked to the Epstein-Barr virus. About 40 people aged 12 and older with these cancers who have no standard treatment options will receive nivolumab every two weeks. The goal is to see if t…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This early-stage trial tests a drug called triapine combined with radiation therapy for people whose glioblastoma or astrocytoma has returned. Triapine blocks enzymes that help cancer cells grow, while radiation kills tumor cells. The study enrolls 30 adults and aims to find the …

This study compares the immunotherapy drug pembrolizumab to the usual chemotherapy plus radiation after surgery for head and neck cancer that has returned or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (like cancer at the surgical edge or spread to…

This study tests two cancer drugs, lurbinectedin and avelumab, in people with a rare and fast-growing bladder cancer called small cell carcinoma. About 45 adults whose cancer has spread after prior treatment will receive the drugs every three weeks for up to 10 years. The goal is…

This study tests an experimental cell therapy for advanced non-small cell lung cancer. Doctors take immune cells from a patient's tumor, grow them in large numbers, and give them back to the patient to fight the cancer. The goal is to see if this treatment can shrink tumors and h…

This study tests whether adding an immunotherapy drug (cemiplimab) to a standard cancer pill (cabozantinib) works better than the pill alone for people with advanced adrenocortical cancer that cannot be removed by surgery or has spread. About 48 adolescents and adults will take p…

This study tests whether adding a second immunotherapy drug (relatlimab) to the standard immunotherapy (nivolumab) can help keep nasopharyngeal cancer from growing or spreading for a longer time. About 156 people with recurrent or metastatic Epstein-Barr virus-associated nasophar…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma. The drug works by attaching to a protein found on these tumors and then killing them with radiation. Abou…

This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to at least two prior treatments. cGVHD is an immune system problem that can occur after a stem cell transplant, causing damage to multiple…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests whether adding a targeted chemotherapy drug (sacituzumab govitecan) to an immunotherapy (pembrolizumab) helps people with advanced bladder cancer that no longer responds to standard immunotherapy. About 320 adults with locally advanced or metastatic urothelial ca…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. The trial enrolls 304 participants with stage IIIB-IV cancer and a specific PD-L1 level. Th…

This study is for adults aged 18-85 with blood cancers that haven't responded well to standard treatments. It tests whether a lower dose of the drug cyclophosphamide, given after a bone marrow transplant, can reduce side effects while still preventing graft-versus-host disease (a…

This study compares three treatment combinations for people with advanced or recurrent endometrial cancer that has specific genetic features (pMMR and TP53 mutated). Participants will receive either standard chemotherapy (carboplatin and paclitaxel) plus the immunotherapy pembrol…

This early-phase trial tests two experimental drugs, peposertib and tuvusertib, together in adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find the safest dose and understand side effects. About 66 participants will take part. This …

This early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults whose diffuse large B-cell lymphoma has returned or not responded to prior treatment. The main goal is to find the safest dose and check for side ef…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study is for adults aged 59 or younger with a high-risk form of acute myeloid leukemia (AML) that is harder to treat. It compares the standard two-drug chemotherapy to four newer treatment combinations, including targeted drugs like venetoclax. The goal is to see which appro…

This study tests a new drug, selinexor, combined with standard chemotherapy (temozolomide) for people with glioblastoma that has returned after initial treatment. The goal is to see if the combination is safer and works better than chemo alone. About 97 adults with a specific typ…

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This study tests whether a combination of two pills (encorafenib and binimetinib) works better than the current drug for hairy cell leukemia that didn't respond to or returned after treatment. About 45 adults with a specific gene mutation (BRAF V600) will take the drugs daily in …

This study tests whether adding two immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy and radiation helps people with early-stage Hodgkin lymphoma live longer with fewer side effects. About 1,875 people aged 5 to 60 with newly diagnosed stage I or I…

This study tests whether adding a round of chemotherapy and the immunotherapy drug pembrolizumab before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the disease getting worse. About 336 participants will be randomly…

This study tests whether a daily pill called olaparib can help keep pancreatic cancer from coming back after surgery and chemotherapy. It is for people whose tumors have specific gene mutations (BRCA1, BRCA2, or PALB2). About 152 participants will receive either olaparib or a pla…

This study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 receive chemotherapy or radiation before the transplant to prepare t…

This study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This study tests a pill called osimertinib in people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion). The drug works by blocking signals that help cancer cells grow. About 46 participants will take the pill daily to see if it shrinks tumors o…

This early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…

This early-phase study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), for adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs shrink tumors. Up to 58 participants, i…

This study tests two drugs, pidnarulex and cemiplimab, in people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find the best dose and see if the combination can slow or stop cancer growth. About 86 adults with a specific type of colo…

This study tests whether adding enasidenib to the usual two-drug therapy (ASTX727 and venetoclax) can help more older adults with newly diagnosed IDH2-mutant acute myeloid leukemia (AML) achieve a deep remission. About 93 participants who are older or unfit for standard chemo wil…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This study tests whether combining two drugs, atezolizumab and selinexor, can shrink tumors in people with a rare cancer called alveolar soft part sarcoma (ASPS). About 27 adults with advanced or spreading ASPS will receive the combination. The goal is to see if this approach wor…

This study looks at whether a simple blood test can find leftover cancer DNA after surgery for urinary tract cancers. About 992 people will be assigned to different immunotherapy plans based on their test results. The goal is to see if giving the drug nivolumab (alone or with rel…

This study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with a rare and aggressive form of prostate cancer that has spread. The drug seeks out and delivers radiation directly to cancer cells that have certain markers. The goal is to see if it can shrink t…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study tests whether a new radioactive tracer called 18F-fluciclovine can find multiple myeloma more accurately than the current tracer. About 60 adults with newly diagnosed or returning myeloma will get both types of PET/CT scans to compare them. The goal is to see if the ne…

This study tests whether a radioactive tracer called [68Ga]Ga-PentixaFor can help PET scans better identify adrenal tumors that release extra hormones. About 80 adults with high aldosterone or cortisol levels and known adrenal masses will receive one injection of the tracer and t…

This study tests whether a special PET scan using a radioactive tracer called 18F-DCFPyL can accurately show how prostate cancer responds to radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will get the scan before and after treatment. The goal …

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study compares HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 women referred for colposcopy or cervical procedures will participate. The goal is to see if self-collection is accurate enough to increase scree…

This study tests whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can lower breast cancer risk more than tamoxifen alone. It includes 66 overweight or obese postmenopausal women at increased risk for breast cancer. The goal is to see if the combination improves …

This study tests whether a new drug, acolbifene, works better than a low dose of tamoxifen to prevent breast cancer in premenopausal women at high risk. Both drugs block estrogen, which can fuel breast cancer growth. About 80 women will take one of the two pills for six months, a…

This early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researcher…

This study tests whether a broccoli seed and sprout extract can help heavy smokers break down and remove cancer-causing chemicals from tobacco. About 135 current smokers will take either the extract or a placebo daily for several weeks. Researchers will measure changes in urine l…

This study tests whether obeticholic acid can prevent Barrett's esophagus from progressing to esophageal cancer. Barrett's esophagus is a condition where the lining of the food pipe changes due to stomach acid and bile exposure, raising cancer risk. The drug works by reducing bil…

This study is for premenopausal women at higher-than-average risk for breast cancer. It tests whether a low dose of tamoxifen can safely reduce breast density, which is linked to cancer risk. About 200 women will take tamoxifen, and doctors will adjust the dose if needed to get t…

This study tests whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with RASopathies—a group of genetic conditions—manage parenting stress. About 70 adult caregivers will participate fully online, watching weekly videos and having coaching sessions ov…

This study tests a device that sends mild electrical pulses to the pelvic floor muscles to help men who have bladder leakage after prostate cancer treatment. About 41 men with moderate leakage for at least 6 months will use the device at home for 20 minutes a day, 5 days a week, …

This study explores whether a normal camping experience can improve the emotional well-being of children with cancer. About 5,000 kids aged 7-17 who are currently in treatment or up to 5 years post-therapy will attend a 7-day camp. Researchers will interview families and observe …

This study follows people who have had a stem cell transplant (and their donors) for years after the procedure. Researchers want to understand long-term health effects, how the transplanted cells change, and how to improve the body's ability to fight cancer. Participants will hav…

This study tests a redesigned surgical tool for removing bladder tumors. Researchers will use the device on bladder specimens from 25 patients who need their bladder removed. The goal is to see if the modified device provides better tissue samples for pathology, helping doctors a…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study follows people with inherited BAP1 gene mutations, which raise the risk of mesothelioma and other cancers. Researchers will track participants over time with exams, scans, and genetic testing to see how and when cancers develop. The goal is to better understand cancer …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why some respond differently to treatments. Participants may undergo apheresis, biopsies,…

This study creates a registry for children, teens, and young adults (ages 1 month to 39 years) diagnosed with very rare solid tumors (fewer than 2 cases per million per year). Researchers will collect medical records, tumor samples, and annual questionnaires over 5 years to bette…

This study looks at whether advanced MRI scans (mpMRI) can better track prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will have regular MRIs alongside standard tests like PSA blood tests and biops…

This pilot study tests whether regular, advanced genetic testing of blood and bone marrow can better monitor children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission from CAR T therapy. The goal is to distinguish who is cured by CAR …

This study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study enrolls people with lung, esophageal, or other chest cancers to collect tumor tissue, normal tissue, blood, and urine samples. Researchers will analyze these samples for genetic and epigenetic changes that may affect how the disease progresses. The goal is to better un…

This study is developing two questionnaires to help measure how visible NF1 tumors are and how they affect appearance concerns. About 110 people with NF1 (aged 8 and older) and caregivers of children with NF1 will complete surveys and join focus groups or interviews. The goal is …

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study follows 300 children and adults with chordoma, a rare bone cancer of the skull base or spine. Researchers will track how the disease progresses over time using imaging, physical exams, and surveys. The goal is to better understand chordoma's behavior to design more eff…

This study looks at whether a radioactive tracer called 18F-DCFPyL, used with PET/CT scans, can find prostate cancer that has come back after treatment. About 350 men with rising PSA levels will get scans over up to 5 years to see how the cancer changes. The goal is to better und…

This study aims to collect blood, tissue, and bone marrow samples from 200 adults with untreated follicular lymphoma. Researchers will monitor participants every 4 to 6 months for up to 5 years to track how the cancer changes and responds to treatment. The goal is to better under…

This study follows people with a gene change (DDX41) that raises the risk of blood cancers like MDS and AML, along with their family members. Researchers will collect health information and samples over 10 years to learn how these inherited risks lead to cancer. No treatment is g…

This study is collecting medical information and biological samples (like blood, saliva, and tumor tissue) from up to 10,000 people with rare solid tumors or a family history of them. The goal is to learn how these tumors grow and change over time, which could lead to better scre…

This study looks at whether a device that tracks pupil changes can measure pain and other unusual sensations in people with Neurofibromatosis Type 1 (NF1). Researchers will test the device on 70 participants aged 1 year and older. The goal is to find a better, more objective way …

This study follows children and adults with medullary thyroid cancer (MTC), often linked to a genetic condition called MEN2. Researchers will track how the cancer grows and affects health over time using regular check-ups, blood tests, and imaging. No treatment is given, but part…

This study collects samples like blood, bone marrow, skin, saliva, and stool from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of blood stem cell disorders that can lead to cancer. Parti…

This study follows 195 adults with KSHV-associated multicentric Castleman's disease (MCD) to better understand how the disease progresses and responds to treatments. Participants receive standard care and regular check-ups over several years. The goal is to improve future treatme…

This study follows people with a rare inherited gene change (DICER1) that raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tumor tissue from 1,500 participants and their close relatives ov…

This long-term study follows up to 4,000 people with inherited bone marrow failure syndromes (IBMFS) and their families to understand why they are prone to certain cancers. Researchers will collect medical records, run lab tests, and track cancer development over time. The goal i…

This study collects blood, urine, saliva, and tissue samples from 500 adults with or at risk for urothelial cancer (bladder, ureter, urethra). Researchers will analyze DNA and other molecular changes to understand how the cancer forms and progresses. Participants provide samples …

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study examines DNA from 354 breast cancer patients who took the drug bevacizumab. Some developed severe high blood pressure, while others did not. Researchers will compare their DNA to find genetic changes that might raise the risk of this side effect. The goal is to better …

This study collects tumor and normal tissue samples from people already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use these samples to study new ways to treat solid tumors. Up to 1,800 adults and children (age 2 and older) with precancerous or c…

This study aims to understand why some people and families are at high risk for melanoma, a serious skin cancer. Researchers will collect medical history, blood or cheek cell samples, and skin biopsies from 3,000 participants with a personal or family history of melanoma. The goa…

This study tracks 500 men aged 30–75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly checkups, blood tests, and prostate MRIs every two years. The goal is to understand how these…

This study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancers. Researchers will use leftover tissue from medical procedures and collect additional samples like blood, saliva, and c…

This study collects blood stem cells from people with DOCK8 deficiency, LAD-1, or GATA2 deficiency to test gene therapy in the lab. Participants receive daily injections to move stem cells into the blood, then donate cells through a procedure called apheresis. The cells are used …

This study aims to collect and analyze medical images and health records from 10,000 men with prostate cancer or at high risk. Researchers hope to find patterns that can improve diagnosis and treatment. No new drugs or procedures are being tested; participants simply allow their …

This study aims to understand the biology of cancers that occur in people with HIV, other immune disorders, or are caused by viruses. Researchers will collect tissue and blood samples from 280 adults to compare genes in cancer cells versus normal cells. The goal is to find geneti…

This study screens patients with advanced solid tumors to find genetic changes in their cancer cells. Based on those results, participants may be matched to a treatment trial that targets their specific mutation. The goal is to improve tumor control and help doctors plan better c…

This study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. The goal is to learn how these growths change over time and to see if a special type of scan (68-Gallium DOTATATE PET/CT) can find them better. Participants will have regular check…

This study enrolls people with cancer who are already participating in other studies at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a person's past, current, and future studies. The goal is to better understand…

This study screens 2,000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. It uses blood and bone marrow tests to find specific markers that can match participants to a treatment trial targeting their cancer type. The goal is to see if the screening …

This study is looking at why some prostate cancers come back after radiation treatment. Researchers will use advanced MRI scans and biopsies to see how the tumor responds to radiation. About 300 men who are about to have radiation or whose cancer has returned after treatment will…

This study collects white blood cells from healthy volunteers to help researchers develop new cancer therapies that use a person's own immune system. Participants must be 18 or older and in good health. The donation process takes 4-6 hours and can be repeated every 21 days.

This study looks at how a stem cell transplant changes a person's DNA and how that affects drug dosing. Researchers will collect blood, skin, hair, and other samples from 88 adults before and after transplant. The goal is to find the best way to test a patient's genes for safe an…

This study collects tumor and healthy tissue samples from up to 2,415 people scheduled for surgery or biopsy for endocrine tumors (thyroid, parathyroid, adrenal, pancreas, or neuroendocrine). Researchers will analyze the samples to find genetic and molecular differences between b…

This study aims to collect blood, urine, tumor tissue, and fluid samples from up to 1,000 people with malignant mesothelioma or other cancers that express mesothelin. Participants will also be followed over time to track their disease and treatments. The samples will be stored an…

This study screens adults with cancers like melanoma, lung, or bladder cancer to see if they can join experimental treatments. Researchers take white blood cells from the patient's tumor or blood, grow them in a lab, and return them to fight the cancer. The goal is to find suitab…

This study follows up with people who previously received a gene therapy or immunotherapy vaccine (using poxviral vectors) for cancers like prostate, liver, breast, colon, or lung cancer. No new treatment is given. Participants get annual health checks for 5 years, then yearly ph…

This study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…

This study collects blood and other samples from adults with cancer to learn how certain immune cells change before and after treatment. No treatment is given as part of this study. Up to 1,750 participants will provide samples, which researchers will analyze to better understand…

This long-term study aims to uncover the causes of cancer by following 200,000 adults aged 30–70 who have never had cancer. Participants complete online surveys, donate blood, urine, and saliva every few years, and share their electronic health records. The goal is to learn how l…

This study follows 300 people aged 30 and older who have or may have a BAP1 gene mutation, which raises the risk of mesothelioma and other cancers. Researchers will use advanced CT scans, blood and urine tests, and minimally invasive camera procedures to find cancers as early as …

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study follows up to 2,000 men with prostate cancer who have certain gene mutations. Researchers want to understand how these genes affect the way the cancer grows, spreads, and responds to treatment. Participants are followed for life through phone calls, emails, and medical…

This study aims to learn more about Li-Fraumeni syndrome (LFS), a genetic condition that raises the risk of several cancers. Researchers will study up to 5,000 people with LFS or related cancer histories to find new genes, understand how the TP53 gene works, and identify factors …

This study examines DNA from 575 breast cancer patients who received the chemotherapy drug paclitaxel. Researchers want to find genetic differences that explain why some patients develop nerve damage (peripheral neuropathy) while others do not. The goal is to identify biomarkers …

This study is testing a new technology called SmartMatch that analyzes tumor tissue from people with recurrent brain or spinal cord tumors. The goal is to see if SmartMatch can quickly identify which drugs might work best for each person's specific tumor. About 80 participants ag…

This study aims to collect and store extra blood, tissue, urine, and tumor samples from children and adults diagnosed with childhood cancers like leukemia, sarcoma, and neuroblastoma. The samples are taken only when already needed for medical care, so no extra procedures are requ…

This study aims to understand where HIV hides in the body when people stop their daily medication for a short time. About 50 adults with HIV will either stay on their regular treatment or pause it for up to 90 days. Researchers will use scans and tissue samples to measure virus l…

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition for up to 20 years. Researchers will collect blood, bone marrow, and other samples to better understand how MDS progresses. Up to 1,100 participants, including healthy donor…

This study aims to better understand inherited forms of kidney and other urinary tract cancers. Researchers will follow up to 5,000 people with a known or suspected genetic risk to track how the disease develops over time and identify the specific genes involved. The goal is to i…

This study collects blood and tumor tissue from adults with gastrointestinal cancers (throat, stomach, gallbladder, liver, pancreas, or colon) to learn how the immune system responds to cancer. Participants give blood samples over several months and may provide tumor tissue if th…

This study follows people with Fanconi anemia, a rare inherited condition that raises the risk of certain cancers, especially squamous cell carcinoma. Researchers will screen 200 participants aged 12 and older every year for up to 10 years using exams, blood tests, and imaging to…

This study aims to learn more about KSHV inflammatory cytokine syndrome (KICS), a newly recognized illness caused by a virus that can also lead to certain cancers. Researchers will collect medical history, blood samples, and imaging from 140 adults with KICS to understand how the…

This study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…

This study follows people with common and rare urinary tract cancers (like bladder, kidney, and testicular) to understand how these cancers behave over time. Researchers will collect medical records, blood, urine, and tumor samples to track disease progression and treatment respo…

This study looks at whether having guided conversations about care preferences helps young adults (ages 18-39) who are about to receive a stem cell transplant, along with their caregivers. Participants will fill out questionnaires and have three talks with a study team member ove…

This study follows 150 adults with Kaposi sarcoma (KS), a tumor caused by a virus, to learn how the disease starts, changes, and may come back. Participants will have regular check-ups, scans, and biopsies over up to 10 years. The goal is to better understand KS, not to test a ne…

This study examines DNA from 162 breast cancer patients who received chemotherapy and either did or did not develop congestive heart failure. Researchers want to find specific gene changes that might increase the risk of heart problems after treatment. The goal is to better under…

This study aims to see if lab-grown tumor models can predict how well heated chemotherapy (HIPEC) works during surgery for cancers that have spread to the abdomen. About 60 adults will have their tumors removed, then some are tested in the lab while others receive the actual heat…

This study follows up to 700 people who have already received radiation therapy for cancer. The goal is to collect information over time about late side effects and how the disease progresses. No new treatments are given; researchers simply gather data from standard follow-up car…

This study collects blood, bone marrow, tumor, and tissue samples from adults with HIV, KSHV, or certain cancers. The goal is to gather samples for research, not to provide treatment. Up to 999 participants will donate samples over time to help scientists learn more about these d…

This study looks at anxiety caused by regular cancer screenings in adults with Fanconi Anemia, a rare inherited condition that raises cancer risk. Researchers will observe 20 participants during their clinic visits, noting body language, worries, and the clinic environment. No tr…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study collects blood, urine, saliva, and tissue samples from people who have or may have cancer, as well as their relatives. The samples are stored and used by researchers to study the genetic and molecular causes of cancer. The goal is to better understand the disease, not …

This study collects blood or cheek swab samples from 1,100 people with cancer who are already in an NCI treatment trial. The goal is to find genetic differences that might affect how well a treatment works or how likely side effects are. Participants must be at least 3 years old …

This study aims to learn more about RASopathies, a group of genetic conditions that can cause developmental issues, birth defects, and increased cancer risk. Researchers will follow up to 500 people of any age who have or may have a RASopathy, along with their family members, for…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to learn more about how these cancers grow and change over time. The goal is to find new ways to diagnose and treat these diseases…

This study aims to find the genetic changes that cause hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to kidney tumors, painful skin bumps, and uterine fibroids. Researchers will study people with known or suspected HLRCC and their family members t…

This study follows 400 people aged 6 and older with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and for 5 years after. The goal is to better underst…

This study aims to collect tissue samples and health information from 300 adults with neuroendocrine neoplasms (NENs), including adrenocortical carcinoma. Researchers will follow participants over time to understand how these rare cancers grow and respond to treatments. The goal …

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas. Participants aged 5 and older will give feedback on existing surveys through group discussions or…

This study aims to understand if CAR T-cell therapy, a treatment for blood cancers like leukemia and lymphoma, can affect thinking skills such as memory and attention in children and young adults aged 5 to 35. Participants will take thinking tests and answer questions at home or …

This study aims to better understand olfactory neuroblastoma, a rare cancer of the nasal cavity. Researchers will follow 525 people aged 3 and older, collecting medical records, blood samples, and smell tests over their lifetime. The goal is to learn how the disease progresses an…

This study looks at whether measuring two proteins (VEGF and MMP) in blood and urine can help predict if a glioblastoma brain tumor will come back within a year after radiation therapy. About 200 adults with this type of brain tumor will provide samples before, during, and after …